目次

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Workflow
1.1.3 Application
1.1.4 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.5.1 Approaches Used To Estimate The Market Size
1.5.1.1 Approach 1: Parent Market Analysis
1.5.1.2 Approach 2: Commodity Flow (Company Share Analysis)
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.7 List Of Secondary Sources
1.8 List Of Abbreviations
1.9 Objectives
1.9.1 Objective - 1:
1.9.2 Objective - 2:
1.9.3 Objective - 3:
1.9.4 Objective - 4:

Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook

Chapter 3 Global Pharmaceutical CDMO Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market outlook
3.1.2 Ancillary Market outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increasing pharmaceutical R&D investments
3.3.1.2 Increasing outsourcing services by pharmaceutical companies
3.3.1.3 Rising investments in R&D
3.3.1.4 Growing consumption of biopharmaceuticals
3.3.1.5 Increasing demand for one-stop-shop CDMOs
3.3.2 Market Restraint Analysis
3.3.2.1 Compliance issues while outsourcing
3.3.2.2 Changing scenarios in developing countries
3.3.2.3 Regulatory and legal compliance
3.4 Global Pharmaceutical CDMO Market Analysis Tools
3.4.1 Porter’s Five Forces Analysis
3.4.2 PESTEL Analysis
3.5 Major Deals & Strategic Alliances Analysis
3.5.1 Expansions
3.5.2 Partnership and Collaboration
3.5.3 Merger and Acquisition
3.5.4 Service and Product launch
3.5.5 Joint Venture
3.6 COVID-19 Impact & Recovery Analysis
3.6.1 COVID-19 Impact
3.6.2 COVID-19 Recovery Analysis
3.6.2.1 Pre-pandemic bioCDMO Capacity Challenges
3.6.2.2 BioCDMO Industry Growth
3.6.2.3 Post-COVID-19 Revenue and Capacity Projections

Chapter 4 Global Pharmaceutical CDMO Market: Product Segment Analysis
4.1 Global CDMO: Market Share Analysis, 2021 & 2030
4.1 Global CDMO Market: Definition and Scope
4.2 API
4.2.1 API Market, 2018 - 2030 (USD Million)
4.2.2 Type
4.2.2.1 Traditional Active Pharmaceutical Ingredient (Traditional API)
4.2.2.1.1 Traditional APIs Market, 2018 - 2030 (USD Million)
4.2.2.2 HP-API
4.2.2.2.1 HP-API Market, 2018 - 2030 (USD Million)
4.2.2.3 Antibody Drug Conjugate
4.2.2.3.1 Antibody Drug Conjugate Market, 2018 - 2030 (USD Million)
4.2.2.4 Others
4.2.2.4.1 Others Market, 2018 - 2030 (USD Million)
4.2.3 Synthesis
4.2.3.1 Synthetic
4.2.3.1.1 Synthetic Market, 2018 - 2030 (USD Million)
4.2.3.1.2 Solid
4.2.3.1.3 Solid Market, 2018 - 2030 (USD Million)
4.2.3.1.4 Liquid
4.2.3.1.5 Liquid Market, 2018 - 2030 (USD Million)
4.2.3.2 Biotech
4.2.3.2.1 Biotech Market, 2018 - 2030 (USD Million)
4.2.4 Drug
4.2.4.1 Innovative
4.2.4.1.1 Innovative Market, 2018 - 2030 (USD Million)
4.2.4.2 Generics
4.2.4.2.1 Generics Market, 2018 - 2030 (USD Million)
4.2.5 Manufacturing
4.2.5.1 Continuous manufacturing
4.2.5.1.1 Continuous Manufacturing Market, 2018 - 2030 (USD Million)
4.2.5.2 Batch manufacturing
4.2.5.2.1 Batch Manufacturing Market, 2018 - 2030 (USD Million)
4.3 Drug Product
4.3.1 Oral solid dose
4.3.1.1 Oral solid dose Market, 2018 - 2030 (USD Million)
4.3.2 Semi-solid dose
4.3.2.1 Semi-solid dose Market, 2018 - 2030 (USD Million)
4.3.3 Liquid Dose
4.3.3.1 Liquid Dose Market, 2018 - 2030 (USD Million)
4.3.4 Others
4.3.4.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Global Pharmaceutical CDMO Market: Work Flow Segment Analysis
5.1 Global CDMO: Market Share Analysis, 2021 & 2030
5.2 Global CDMO Market: Definition and Scope
5.3 Clinical
5.3.1 Clinical Market, 2018 - 2030 (USD Million)
5.4 Commercial
5.4.1 Commercial Market, 2018 - 2030 (USD Million)

Chapter 6 Global Pharmaceutical CDMO Market: Application Segment Analysis
6.1 Global CDMO Market: Definition and Scope
6.2 Global CDMO: Market Share Analysis, 2021 & 2030
6.3 Oncology
6.3.1 Oncology Market, 2018 - 2030 (USD Million)
6.4 Hormonal
6.4.1 Hormonal Market, 2018 - 2030 (USD Million)
6.5 Glaucoma
6.5.1 Glaucoma Market, 2018 - 2030 (USD Million)
6.6 Cardiovascular Disease
6.6.1 Cardiovascular Disease Market, 2018 - 2030 (USD Million)
6.7 Diabetes
6.7.1 Diabetes Market, 2018 - 2030 (USD Million)
6.8 Others
6.8.1 Others Market, 2018 - 2030 (USD Million)

Chapter 7 Global Pharmaceutical CDMO Market: Regional Analysis
7.1 Global Contract Development & Manufacturing Organization: Market Share Analysis, 2021 & 2030
7.2 North America
7.2.1 North America Market, 2018 - 2030 (USD Million)
7.2.1.1 U.S.
7.2.1.1.1 U.S. Market, 2018 - 2030 (USD Million)
7.2.1.2 Canada
7.2.1.2.1 Canada Market, 2018 - 2030 (USD Million)
7.3 Europe
7.3.1 Europe Market, 2018 - 2030 (USD Million)
7.3.1.1 UK
7.3.1.1.1 UK Market, 2018 - 2030 (USD Million)
7.3.1.2 Germany
7.3.1.2.1 Germany Market, 2018 - 2030 (USD Million)
7.3.1.3 France
7.3.1.3.1 France Market, 2018 - 2030 (USD Million)
7.3.1.4 Italy
7.3.1.4.1 Italy Market, 2018 - 2030 (USD Million)
7.3.1.5 Spain
7.3.1.5.1 Spain Market, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Market, 2018 - 2030 (USD Million)
7.4.1.1 China
7.4.1.1.1 China Market, 2018 - 2030 (USD Million)
7.4.1.2 India
7.4.1.2.1 India Market, 2018 - 2030 (USD Million)
7.4.1.3 Japan
7.4.1.3.1 Japan Market, 2018 - 2030 (USD Million)
7.4.1.4 Australia
7.4.1.4.1 Australia Market, 2018 - 2030 (USD Million)
7.4.1.5 South Korea
7.4.1.5.1 South Korea Market, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America Market, 2018 - 2030 (USD Million)
7.5.1.1 Brazil
7.5.1.1.1 Brazil Market, 2018 - 2030 (USD Million)
7.5.1.2 Mexico
7.5.1.2.1 Mexico Market, 2018 - 2030 (USD Million)
7.5.1.3 Argentina
7.5.1.3.1 Argentina Market, 2018 - 2030 (USD Million)
7.6 MEA
7.6.1 MEA Market, 2018 - 2030 (USD Million)
7.6.1.1 South Africa
7.6.1.1.1 South Africa Market, 2018 - 2030 (USD Million)
7.6.1.2 South Arabia
7.6.1.2.1 South Arabia Market, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape
8.1 Company Profiles
8.1.1 Bushu Pharmaceuticals LTD.
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Service benchmarking
8.1.1.4 Strategic initiatives
8.1.2 NIPRO Corporation
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Service benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Thermo Fisher Scientific Inc.
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Service Benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Samsung Biologics
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Service benchmarking
8.1.4.4 Strategic initiatives
8.1.5 Laboratory Corporation of America Holdings
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Service benchmarking
8.1.5.4 Strategic initiatives
8.1.6 Siegfried Holding AG
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Service benchmarking
8.1.6.4 Strategic initiatives
8.1.7 Catalent, Inc.
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Service benchmarking
8.1.7.4 Strategic initiatives
8.1.8 Lonza Group AG
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Service benchmarking
8.1.8.4 Strategic initiatives
8.1.9 Recipharm AB
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Service benchmarking
8.1.9.4 Strategic initiatives
8.1.10 Piramal Pharma Solutions
8.1.10.1 Company overview
8.1.10.2 Service benchmarking
8.1.10.3 Strategic initiatives
8.1.11 CordenPharma International
8.1.11.1 Company overview
8.1.11.2 Financial Performance
8.1.11.3 Service benchmarking
8.1.11.4 Strategic initiatives
8.1.12 Cambrex Corporation
8.1.12.1 Company overview
8.1.12.2 Financial performance
8.1.12.3 Service benchmarking
8.1.12.4 Strategic initiatives
8.1.13 Wuxi AppTec
8.1.13.1 Company overview
8.1.13.2 Financial performance
8.1.13.3 Service benchmarking
8.1.13.4 Strategic initiatives
8.2 Company Market Share Analysis
8.2.1 Company Market Share Analysis in the Global CDMO Market
8.2.1.1 Analysis
8.2.2 Company Market Share Analysis in the Japan CDMO Market
8.2.2.1 Analysis

List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Pharmaceutical companies’ total R&D spending in 2020
Table 4 Expansion
Table 5 Partnership and Collaboration
Table 6 Merger and Acquisition
Table 7 Service and Product launch
Table 8 Joint Venture
Table 9 Various ADCs approved by the FDA is as follows:
Table 10 Death and cause of death

List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Global CDMO market snapshot (2021) (in USD Million)
Fig. 9 Global CDMO market segmentation
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 FDA approval and biosimilar product launch trends from 2015 to 2020
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 Porter’s five forces analysis
Fig. 17 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 18 10-year bioCDMO revenue: Global mAbs, vaccines, and recombinant biologics contract manufacturing.
Fig. 19 Top bioCDMO revenue for external contract manufacture of mAbs, vaccines and recombinant biologics.
Fig. 20 Percentage of organizations manufacturing 100% in-house, 2006-2022, (no outsourced manufacturing)
Fig. 21 Global CDMO market Product outlook: Segment dashboard
Fig. 22 Global CDMO market: Product movement analysis
Fig. 23 Active Pharmaceutical Ingredient
Fig. 24 API market, 2018 - 2030 (USD Million)
Fig. 25 Traditional APIs market, 2018 - 2030 (USD Million)
Fig. 26 HP-API market, 2018 - 2030 (USD Million)
Fig. 27 Antibody drug conjugate market, 2018 - 2030 (USD Million)
Fig. 28 Others market, 2018 - 2030 (USD Million)
Fig. 29 Synthetic market, 2018 - 2030 (USD Million)
Fig. 30 Solid market, 2018 - 2030 (USD Million)
Fig. 31 Liquid market, 2018 - 2030 (USD Million)
Fig. 32 Biotech market, 2018 - 2030 (USD Million)
Fig. 33 Innovative market, 2018 - 2030 (USD Million)
Fig. 34 Share (estimate in % ) accounted for by generics in pharmaceutical market (2019)
Fig. 35 Generics market, 2018 - 2030 (USD Million)
Fig. 36 Continuous manufacturing process of tablets
Fig. 37 Continuous manufacturing market, 2018 - 2030 (USD Million)
Fig. 38 Batch manufacturing process
Fig. 39 Batch manufacturing market, 2018 - 2030 (USD Million)
Fig. 40 Classification of solid dosage forms
Fig. 41 Oral solid dose market, 2018 - 2030 (USD Million)
Fig. 42 Semi-solid dose market, 2018 - 2030 (USD Million)
Fig. 43 Liquid dose market, 2018 - 2030 (USD Million)
Fig. 44 Others market, 2018 - 2030 (USD Million)
Fig. 45 Global CDMO market work flow outlook: Segment dashboard
Fig. 46 Global CDMO market: Work flow movement analysis
Fig. 47 Clinical market, 2018 - 2030 (USD Million)
Fig. 48 Commercial market, 2018 - 2030 (USD Million)
Fig. 49 Global CDMO market synthesis outlook: segment dashboard
Fig. 50 Global CDMO market: application movement analysis
Fig. 51 Number of cancer cases in 2020 (in millions)
Fig. 52 Oncology market, 2018 - 2030 (USD Million)
Fig. 53 Hormonal market, 2018 - 2030 (USD Million)
Fig. 54 Projected prevalence of glaucoma
Fig. 55 Projection of the number of people with primary open angle glaucoma in 2050
Fig. 56 Glaucoma market, 2018 - 2030 (USD Million)
Fig. 57 Cardiovascular disease market, 2018 - 2030 (USD Million)
Fig. 58 Diabetes market, 2018 - 2030 (USD Million)
Fig. 59 Others market, 2018 - 2030 (USD Million)
Fig. 60 Global CDMO market regional outlook: segment dashboard
Fig. 61 Global CDMO market: regional movement analysis
Fig. 62 North America market, 2018 - 2030 (USD Million)
Fig. 63 U.S. market, 2018 - 2030 (USD Million)
Fig. 64 Canada market, 2018 - 2030 (USD Million)
Fig. 65 Europe market, 2018 - 2030 (USD Million)
Fig. 66 UK market, 2018 - 2030 (USD Million)
Fig. 67 Germany market, 2018 - 2030 (USD Million)
Fig. 68 France market, 2018 - 2030 (USD Million)
Fig. 69 Italy market, 2018 - 2030 (USD Million)
Fig. 70 Spain market, 2018 - 2030 (USD Million)
Fig. 71 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 72 China market, 2018 - 2030 (USD Million)
Fig. 73 India market, 2018 - 2030 (USD Million)
Fig. 74 Japan market, 2018 - 2030 (USD Million)
Fig. 75 Australia market, 2018 - 2030 (USD Million)
Fig. 76 Australia market, 2018 - 2030 (USD Million)
Fig. 77 Latin America market, 2018 - 2030 (USD Million)
Fig. 78 Brazil market, 2018 - 2030 (USD Million)
Fig. 79 Mexico market, 2018 - 2030 (USD Million)
Fig. 80 Mexico market, 2018 - 2030 (USD Million)
Fig. 81 MEA market, 2018 - 2030 (USD Million)
Fig. 82 South Africa market, 2018 - 2030 (USD Million)
Fig. 83 South Arabia market, 2018 - 2030 (USD Million)
Fig. 84 Financial Performance of Nirpo Corporation
Fig. 85 Financial Performance of Thermo Fisher Scientific, Inc.
Fig. 86 Financial Performance of Samsung Biologics
Fig. 87 Financial Performance of LabCorp
Fig. 88 Financial Performance of Siegfried Holding AG
Fig. 89 Financial Performance of Catalent, Inc.
Fig. 90 Financial Performance of Lonza
Fig. 91 Financial Performance of Recipharm AB
Fig. 92 Financial Performance of Piramal Pharma Solutions
Fig. 93 Financial Performance of WuXi AppTec
Fig. 94 Company Market Share Analysis in the Global CDMO Market (2021)
Fig. 95 Company Market Share Analysis in the Japan CDMO Market (2021)